Stefania Vultaggio
IFOM(IT)Vifor Pharma (United States)(US)
Publications by Year
Research Areas
Histone Deacetylase Inhibitors Research, Epigenetics and DNA Methylation, Protein Degradation and Inhibitors, Synthesis and biological activity, Cancer-related gene regulation
Most-Cited Works
- → Toward Highly Potent Cancer Agents by Modulating the C-2 Group of the Arylthioindole Class of Tubulin Polymerization Inhibitors(2012)120 cited
- → New Pyrrole Derivatives with Potent Tubulin Polymerization Inhibiting Activity As Anticancer Agents Including Hedgehog-Dependent Cancer(2014)91 cited
- → Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 1: High-Throughput Screening and Preliminary Exploration(2017)73 cited
- → Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structure–Activity Relationship(2017)70 cited
- → New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity, and Repression of Hedgehog-Dependent Cancer(2015)58 cited
- → New 6- and 7-heterocyclyl-1H-indole derivatives as potent tubulin assembly and cancer cell growth inhibitors(2018)39 cited
- → Synthesis and Biological Evaluation of N-Hydroxyphenylacrylamides and N-Hydroxypyridin-2-ylacrylamides as Novel Histone Deacetylase Inhibitors(2009)33 cited
- → Tranylcypromine‐Based LSD1 Inhibitors: Structure‐Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation(2020)32 cited
- → Adherence of systematic reviews to Cochrane RoB2 guidance was frequently poor: a meta epidemiological study(2022)31 cited
- → Discovery of Reversible Inhibitors of KDM1A Efficacious in Acute Myeloid Leukemia Models(2020)25 cited